POXEL — Poxel SA Share News
0.000.00%
Last trade - 00:00- €9.32m
- €68.25m
- €6.64m
Brief: Poxel Initiates Study As Part Of Clinical Program For PXL770
Brief: Poxel Q2 Revenue Down At 8.3 Million Euros
Brief: Metavant, Poxel Announce Positive Topline Safety, PK/PD Results Of Imeglimin
Brief: Poxel And Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results For Imeglimin Phase 3 Trial (TIMES 3) In Japan
Brief: Poxel Updates On PXL065 Phase 1A Single Ascending Dose Trial
Brief: Poxel Q1 Revenue Down At EUR 14.9 Million
Brief: Poxel Initiates Phase 2A Program For Pxl770 For Treatment Of Nash
Brief: Poxel FY Operating Result Turns To Profit Of 12.5 Million Euros
Brief: Poxel Q4 Revenue Grows To 19.6 Million Euros
Brief: Poxel Announces Presentation Of PXL065 Data
Brief: Poxel Announces Initiation Of Part 2 Of Phase 1A Study For Pxl065, Which Is Being Developed For Treatment Of Nash
Brief: Poxel Presents Data For PXL770 And PXL065 For The Treatment of NASH
Brief: Poxel Reports Q3 Total Revenues Of 17.5 Million Euros
Brief: Poxel Announces Completion Of Patient Enrollment For Times 2 Trial In Phase 3 Registration Program For Imeglimin In Japan
Brief: Poxel Presents Complete PXL770 Phase 1 Results
Brief: Poxel H1 Operating Loss Turns To Profit Of 6.4 Million Euros
Brief: Poxel Signs Acquisition Agreement With Deuterx For Drx-065
Brief: Poxel Announces Completion Of Patient Enrollment For The Times 3 Trial
Brief: Poxel Announces Favorable Results For PXl770 Phase 1B Multiple Ascending Dose Trial And Drug-Drug Interaction Study